Loading
Lexaria Bioscience Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BUNKA CHRISTOPHER, was filed 30 Jul 2025.
Lexaria Bioscience Corp.: what insiders have been doing
This page follows insider dealings at Lexaria Bioscience Corp. as filed with SEC (Form 4), a company from the Health Care sector. In the past year (23 October 2025 to 23 October 2026), 1 filing came from 1 insider.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought Lexaria Bioscience Corp. shares on the open market in the past twelve months.
Compared with its exchange (3,167 companies, median 24 filings), a count of 1 filing is below the norm. The full history, which starts in 2016, counts 111 purchases against 7 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 August 2025), the company reported net income of -11.9 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
176
Thresholds
n/a
Buy Volume
€339,544
111 ops. · all time
Sell Volume
€154,025
7 ops. · all time
Who traded when
BuySaleRichard Christopher3 buys
Christopher Bunka2 buys
John Martin Docherty1 buy
Vanessa Carle1 buy
William Edward McKechnie1 buy
Since the insiders bought
- -56.6%Entry US$13.50 · Close at T+365 US$5.86
- -56.6%Entry US$13.50 · Close at T+365 US$5.86
- -56.6%Entry US$13.50 · Close at T+365 US$5.86
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended August 2025 · cache
US$2.80
Analyst consensus
1 analystsUS$82.50Target US$82.50(+2846%)US$82.50
Income statement
RevenueUS$705.9k
Gross profitUS$703.2k100% margin
EBITDA-US$11.8M-1671% margin
Net income-US$11.9M-1686.0% margin
Valuation
P/Book1.0x
Beta0.60
Balance sheet & cash
Market capUS$5.9M
Total debtUS$109.3k
Free Cash Flow-US$10.6M
Debt / Equity2%
Profitability & ownership
ROE-162.8%
ROA-81.3%
% insiders3.3%
% institutions6.6%
Last declaration on 18 March 2026
Declarations176 total
100,000 shares0common sharesSEC:0001103780-26-000001:0
11,900 shares@ US$0.91311.8% of flowcommon sharesSEC:0001348362-25-000016:1
Canonical exit: 28 Oct 2025 (T+90)
5,376 shares@ US$0.928100.0% of flowcommon sharesSEC:0001348362-25-000014:0
Canonical exit: 27 Oct 2025 (T+90)
15,600 shares@ US$0.921521.7% of flowcommon sharesSEC:0001348362-25-000016:0
Canonical exit: 27 Oct 2025 (T+90)
5,000 shares@ US$0.9063100.0% of flowcommon sharesSEC:0001348362-25-000015:0
Canonical exit: 27 Oct 2025 (T+90)
750 shares@ US$0.914.6% of flowcommon sharesSEC:0001348362-25-000013:0
Canonical exit: 27 Oct 2025 (T+90)
15,000 shares@ US$0.909419.6% of flowcommon sharesSEC:0001348362-25-000012:0
Canonical exit: 27 Oct 2025 (T+90)
100,000 shares0Restricted Stock AwardSEC:0001348362-25-000001:0
27,172 shares@ US$2.4751.4% of flowcommon sharesSEC:0001348362-24-000006:1
Canonical exit: 3 Mar 2025 (T+90)
22,828 shares@ US$2.243680.4% of flowcommon sharesSEC:0001348362-24-000006:0
Canonical exit: 2 Mar 2025 (T+90)
1,600 shares@ US$3.1353.5% of flowcommon sharesSEC:0001855763-24-000013:0
Canonical exit: 10 Nov 2024 (T+90)
2,567 shares@ US$4.0074.5% of flowcommon sharesSEC:0001855763-24-000012:0
2,500 shares@ US$1.1520.9% of flowcommon sharesSEC:0001855763-24-000011:0
1,500 shares@ US$2.844646.5% of flowCommon SharesSEC:0001855763-23-000001:0
Canonical exit: 10 May 2023 (T+90)
121 shares@ US$2.09100.0% of flowcommon sharesSEC:0001855763-22-000020:0
Canonical exit: 12 Jan 2023 (T+90)
16,600 shares@ US$2.106.7% of flowcommon sharesSEC:0001855763-22-000014:1
21,900 shares@ US$1.98878.3% of flowcommon sharesSEC:0001855763-22-000014:0
5,000 shares@ US$1.95857.7% of flowcommon sharesSEC:0001855763-22-000006:0
1,799 shares@ US$2.00721.6% of flowcommon sharesSEC:0001855763-22-000005:0
1,501 shares@ US$2.0115.3% of flowcommon sharesSEC:0001855763-22-000004:1
1,700 shares@ US$2.00820.6% of flowcommon sharesSEC:0001855763-22-000004:0
Common SharesTSXSEDI:3665774
13,191 sharesCommon SharesTSXSEDI:3661658
273,543 sharesCommon SharesTSXSEDI:3661768
54,075 sharesCommon SharesTSXSEDI:3661636
25 of 176 declarations
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a company focused on developing delivery technologies for cannabinoids and other bioactive molecules. It aims to enhance the absorption and efficacy of cannabinoid-based products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
